Total parenteral nutrition (TPN) is a lifeâsaving therapy administered to millions of patients. However, it is associated with significant adverse effects, namely liver injury, risk of infections, and metabolic derangements. In this review, the underlying causes of TPNâassociated adverse effects, specifically gut atrophy, dysbiosis of the intestinal microbiome, leakage of the epithelial barrier with bacterial invasion, and inflammation are first described. The role of the bile acid receptors farnesoid X receptor and Takeda G proteinâcoupled receptor, of pleiotropic hormones, and growth factors is highlighted, and the mechanisms of insulin resistance, namely the lack of insulinotropic and insulinomimetic signaling of gutâoriginating incretins as well as the potentially toxicity of phytosterols and proâinflammatory fatty acids mainly released from soybean oilâbased lipid emulsions, are discussed. Finally, novel approaches in the design of next generation lipid delivery systems are proposed. Propositions include modifying the physicochemical properties of lipid emulsions, the use of lipid emulsions generated from sustainable oils with favorable ratios of antiâinflammatory nâ3 to proâinflammatory nâ6 fatty acids, beneficial adjuncts to TPN, and concomitant pharmacotherapies to mitigate TPNâassociated adverse effects.